Data showed that in vivo treatment of primary xenografts with the CK2 inhibitor, CX-4945, in combination with rapamycin, results in the inhibition of mTOR pathway and reduced transcription of the MTOR gene in leukemia cells in both BM and spleen (Fig. S13). The gene discussed is MTOR; the disease is leukemia.